GSK plc (GSK) Form 6-K — Jul 13, 2026
GSK announced positive interim results from the registrational Phase II AZUR-1 trial evaluating Jemperli in patients with locally advanced rectal cancer. The trial met its primary objective, demonstrating a sustained clinical complete response rate at 12 months, with some patients showing no detectable signs of cancer one year or more after treatment. The study involved 154 participants and suggests that Jemperli could potentially eliminate the need for chemotherapy, radiation, and surgery in this patient population. GSK plans to share the data with health authorities to support regulatory review, including an accelerated review in the US.
Key figures
- Dosage Mg
- 500
- Subtype Prevalence
- 5-10%
- Trial Participants
- 154
- Rectal Cancer Global Incidence
- 730000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.